Abuse liability assessment in preclinical drug development: Predictivity of a translational approach for abuse liability testing using methylphenidate in four standardized preclinical study models

Journal of Pharmacological and Toxicological Methods

Volumn 70, Issue 3, 2014, Pages 295-309

  Teuns, Greet B A ^a   Geys, Helena M ^a,b   Geuens, Sonja M A ^a   Stinissen, Piet ^b   Meert, Theo F ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

Author keywords

Abuse potential; Conditioned place preference; Drug discrimination; Methylphenidate; Preclinical drug development; Predictivity; Rat; Self administration; Translational approach; Withdrawal

Indexed keywords

DEXAMPHETAMINE; METHYLPHENIDATE; CENTRAL STIMULANT AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BODY TEMPERATURE; CALCULATION; CIRCADIAN RHYTHM; CONDITIONED PLACE PREFERENCE TEST; CONTROLLED STUDY; DISCRIMINATION LEARNING; DRUG ABUSE; DRUG DEPENDENCE; DRUG DISCRIMINATION TEST; FOOD INTAKE; HABITUATION; LOCOMOTION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PREDICTION; RAT; REINFORCEMENT; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICOKINETICS; TRANSLATIONAL RESEARCH; WEIGHT GAIN; ANIMAL; BLOOD; DISEASE MODEL; DOSE RESPONSE; DRUG SCREENING; DRUG SELF ADMINISTRATION; HUMAN; PROCEDURES; RISK ASSESSMENT; SPRAGUE DAWLEY RAT; SUBSTANCE-RELATED DISORDERS;

RATTUS; RODENTIA;

ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; METHYLPHENIDATE; RATS; RATS, SPRAGUE-DAWLEY; RISK ASSESSMENT; SELF ADMINISTRATION; SUBSTANCE-RELATED DISORDERS;

EID: 84938536294     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2014.02.002     Document Type: Article

References (76)

1. American Veterinary Medical Association (AVMA) Panel on euthanasia 2000-report. Journal of the American Veterinary Medical Association 2001, 218(5):669-696.
2. Askenasy E., Taber K., Yang P., Dafny N. Methylphenidate (Ritalin): Behavioural studies in the rat. The International Journal of Neuroscience 2007, 177:757-794.
3. Ator N., Griffiths R. Principles of drug abuse liability assessment in laboratory animals. Drug and Alcohol Dependence 2003, 70:S55-S72.
4. Baldo B., Kelley A. Discrete neurochemical coding of distinguishable motivational processes: Insights from nucleus accumbens control of feeding. Psychopharmacology 2007, 191:439-459.
5. Bardo M. Conditioned place preference: What does it add to our preclinical understanding of drug reward?. Psychopharmacology 2000, 153(1):31-43.
6. Belgian Law Protection of vertebrate animals used for experimental and other scientific purposes. Royal Decree of November 14, 1993 for the protection of laboratory animals 1991, October 18.
7. Bonson K., Sun S. Draft decision tree for assessment of abuse potential. Science of abuse liability assessment, FDA controlled substance staff, Center for Drug Evaluation and Research 2011, US Food and Drug Administration. Legacy Hotel, Rockville, (Public information).
8. Botly L., Burton C., Rizos Z., Fletcher P. Characterization of methylphenidate self-administration and reinstatement in the rat. Psychopharmacology 2008, 199:55-66.
9. Brandon C., Marinelli M., White F. Adolescent exposure to methylphenidate alters the activity of rat midbrain dopamine neurons. Biological Psychiatry 2003, 54:1338-1344.
10. Broadbear J., Winger G., Woods J. Self-administration of fentanyl, cocaine and ketamine: Effects on the pituitary-adrenal axis in rhesus monkeys. Psychopharmacology 2004, 176:398-406.
11. Carroll M., Lac S. Acquisition of IV amphetamine and cocaine self-administration in rats as a function of dose. Psychopharmacology 1997, 129(3):206-214.
12. Challman T., Lipsky J. Methylphenidate: Its pharmacology and uses. Mayo Clinic Proceedings 2000, 75:711-721.
13. Concerta® (Methylphenidate HCl) Product monograph 2012.
14. Concerta® Prescription Label (present). http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a88218c-5b18-4220-8f56-526de1a276cd.
15. Convention on Psychotropic Substances List of psychotropic substances under international control 1971.
16. CPDD: The College on Problems of Drug Dependence Conference on preclinical abuse liability testing: Current methods and future challenges 2006.
17. Cunningham C.L., Ferree N.K., Howard M.A. Apparatus bias and place conditioning with ethanol in mice. Psychopharmacology 2003, 170:409-422.
18. Cunningham C.L., Gremel C.M., Groblewski P.A. Drug-induced conditioned place preference and aversion in mice. Nature Protocols 2006, 1(4):1662-1670.
19. Dela Cruz A., Herin D., Grady J., Cunningham K. Novel approach to data analysis in cocaine-conditioned place preference. Behavioral Pharmacology 2009, 20:720-730.
20. Dela Peña I., Yoon S.Y., Lee J.C., dela Peña J.B., Sohn A.R., Ryu J.H., et al. Methylphenidate treatment in the spontaneously hypertensive rat: Influence on methylphenidate self-administration and reinstatement in comparison with Wistar rats. Psychopharmacology 2012, 221:217-226.
21. Drug Information Portal Drug Lib.com. Amphetamine http://www.druglib.com/activeingredient/amphetamine/.
22. Dunnett C.W. A multiple comparison procedure for comparing several treatments with a control. Journal of the American Statistical Association 1955, 50:1096-1121.
23. EMA: EMEA/CHMP/SWP/94227/2004.Adopted by CHMP Guideline on the non-clinical investigation of the dependence potential of medicinal products 2006.
24. European Convention (ETS No. 123) for the protection of vertebrate animals used for experimental and other scientific purposes. Council Directive of November 24, 1986 (86/609/EEG) on the approximation of laws, regulations and administrative provisions of the member states regarding the protection of animals used for experimental and other scientific purposes, complemented with the Commission Recommendation of 18 June 2007 (2007/526/EC) on guidelines for the accommodation and care of animals used for experimental and other scientific purposes.
25. Evans C., Blackburn D., Butt P., Dattani D. Use and abuse of methylphenidate in attention-deficit/hyperactivity disorder: Beware of legitimate prescriptions being diverted. Canadian Pharmacists Journal/Revue des Pharmaciens du Canada 2004, 137:30.
26. FDA-DEA.Office of diversion Control Controlled substance schedules 2012.
27. FDA at the dialogue session on abuse potential Comments by CSS at F2F meeting in Bethesda, MD. Public information 2010.
28. FDA U.S.Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Guidance for industry. Assessment of abuse potential of drugs. Draft guidance 2010.
29. Fleckenstein A., Pogun S., Carroll F., Kuhar M. Recovery of dopamine transporter binding and function after intrastriatal administration of the irreversible inhibitor RTI-76 {3β-(3p-chlorophenyl)tropan-2β-carboxylic acid p-isothiocyanatophenylethyl ester hydrochloride}. The Journal of Pharmacology and Experimental Therapeutics 1996, 279(1):200-206.
30. Gaytan O., Yang P., Swann A., Dafny N. Diurnal differences in sensitization to methylphenidate. Brain Research 2000, 864:24-39.
31. Grund T., Lehmann K., Bock N., Rothenberger A., Teuchert-Noodt G. Influence of methylphenidate on brain-development - An update of recent animal experiments. Behaviour and Brain Functions 2006, 2(2):1-14.
32. Hajnal A., Székely M., Gálosi R., Lénárd L. Accumbens cholinergic interneurons play a role in the regulation of body weight and metabolism. Physiology & Behavior 2000, 70:95-103.
33. HHS US Department of health and Services Substance Abuse and Mental Health Services Administration (SAMHSA). Center for Substance Abuse Treatment. Advisory news for the treatment field 2006, May, 5(2).
34. Hochberg, Tamhane Multiple comparison procedures 1987, John Wiley & Sons.
35. Horton D., Potter D., mead A. A translational pharmacology approach to understanding the predictive value of abuse potential assessments. Behavioural Pharmacology 2013, 24:410-436.
36. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Harmonised Tripartite Guideline. Guidance of nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. M3(R2). Current step 4-version 2009, (Current step 4-version).
37. Janowsky D., Leichner P., Clopton P., Judd L., Parker D., Huey L. Comparison of oral and intravenous methylphenidate. Psychopharmacology 1978, 59:75-78.
38. Kerenyi A., Koranyi E., Sarwer-Foner G. The use of intravenous methylphenidate (Ritalin) in psychiatric interviewing. Canadian Medical Association Journal 1959, 80:963-967.
39. Kollins S., MacDonald E., Rush C. Assessing the abuse potential of methylphenidate in nonhuman and human subjects. A review. Pharmacology Biochemistry and Behavior 2001, 68:611-627.
40. Koob G. Animal models of drug addiction. Definitions and validation of animal models. Psychopharmacology: The fourth generation of progress 2000.
41. Kuczenski R., Segal D. Exposure of adolescent rats to oral methylphenidate: Preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. The Journal of Neuroscience 2002, 22(16):7264-7271.
42. Larsson J. Optimum rate of administration of propofol for induction of anaesthesia in rats. British Journal of Anaesthesia 1994, 73(5):692-694.
43. Levi M., Divine B., Hanig J., Doerge D., Vanlandingham M., George N., et al. A comparison of methylphenidate-, amphetamine-, and methamphetamine-induced hyperthermia and neurotoxicity in male Sprague-Dawley rats during the waking (lights off) cycle. Neurotoxicology and Teratology 2012, 34(2):253-262.
44. Matthey Johnson, Smith Macfarlan Safety data sheet methylphenidate hydrochloride, CAS-no. 298-59-9 2006, (Reach).
45. Meert T., De Haes P., Vermote P., Janssen P. A pharmacological validation of ritanserin and risperidone in the drug discrimination test procedure in the rat. Drug Development Research 1990, 19:353-373.
46. Morton W., Stockton G. Use and abuse of methylphenidate in attention-deficit/hyperactivity disorder. Primary care companion. Journal of Clinical Psychiatry 2000, 2(5):159-164.
47. Naguib M., Hammond D., Schmid P., Baker M., Cutkomp J., Queral L., et al. Pharmacological effects of intravenous melatonin: Comparative studies with thiopental and propofol. British Journal of Anaesthesia 2003, 90:504-507.
48. Neter Wasserman, Kutner Applied linear statistical models 1990, IRWIN, Boston.
49. NHS Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Review of Technology Appraisal 13. Technology Appraisal 98 2009.
50. Peana A., Muggironi G., Diana M. Acetaldehyde-reinforcing effects: A study on oral self-administration behaviour. Frontiers in Psychiatry 2010, 1:1-6. (article 23).
51. Piazza P., Deroche-Gamonent V., Rouge-Pont F., Le Moal M. Vertical shifts in self-administration dose-response functions predict a drug-vulnerable phenotype predisposed to addiction. The Journal of Neuroscience 2000, 20(11):4226-4232.
52. Pilotte N.S., Sharpe L.G., Rountree S.D., Kuhar M.J. Cocaine withdrawal reduces dopamine transporter binding in the shell of the nucleus accumbens. Synapse 1996, 1:87-92.
53. Ritalin Produced by the Students of MIT Course 5.22J / 10.02J / BEH 105J. Biotechnology and Engineering May 2001, 1-589.
54. RTECS®: Registry of Toxic Effects of Chemical Substances (RTECS®) database d-Amphetamine (CAS 51-63-8) 2013.
55. Russell V., Sagvolden T., Johansen E. Animal models of attention deficit hyperactivity disorder. Behavioral and Brain Functions 2005, 1(9):1-17.
56. Sagvolden T., Johansen E. Rat models of ADHD. Current Topics in Behavioral Neurosciences 2012, 9:301-315.
57. Separham A., Eghbal M.-A., Tamizi E., Jouyban A. A quantitative structure - Toxicity relationship of drugs on rat. Revista Colombiana de ciencias químico - Farmacéuticas 2011, 40(1):27-46.
58. Shippenberg T., Koob G. Recent advances in animal models of drug addiction. Psychopharmacology: The fifth generation of progress 2002, (Chapter 97).
59. Shire Canada Inc. Product monograph AdderallX® 2011.
60. Shram M., Quin A., Chen N., Faulknor J., Luong D., Sellers E., et al. Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: Examination of current bioequivalence criteria. Clinical Therapeutics 2012, 34(5):1170-1181.
61. Siegel S., Castellan N. Nonparametric statistics for the behavioral sciences 1988, McGraw-Hill International Editions. 2nd ed.
62. Sigma-Aldrich Safety data sheet according to Regulation (EC) No. 1907/2006. Version 5.0 revision date 05.10.2012. Methylphenidate hydrochloride. CAS-no. 298-59-9 2012.
63. 14C-propofol after intravenous dosing to rat, dog and rabbit. Xenobiotica 1991, 21:1243-1256.
64. Spyraki C., Fibiger H., Phillips A. Dopaminergic substrates of amphetamine-induced place preference conditioning. Brain Research 1982, 253(1-2):185-193.
65. Swanson J., Volkow N. Serum and brain concentrations of methylphenidate: Implications for use and abuse. Neuroscience and Biobehavioral Reviews 2003, 27:615-621.
66. Teuns G., Geys H. Intravenous self-administration studies in rats: Technical developments to improve animal welfare, life expectancy and experimental face validity. Internal report 2013, (unpublished).
67. Teuns G., Lammens L. Single dose study of various psycho-active drugs in the rat: Toxicokinetic study. Internal report 2012, (unpublished).
68. Van Ree J., Gerrits M., Vanderschuren L. Opioids, reward and addiction: An encounter of biology, psychology, and medicine. Pharmacological Reviews 1999, 51(2):341-396.
69. Verbeke G., Molenberghs G. Linear mixed models for longitudinal data 2000, Springer Series in Statistics, New York.
70. Volkow N., Wang G., Baler R. Reward, dopamine and the control of food intake: Implications for obesity. Trends in Cognitive Sciences 2011, 15(1):37-46.
71. Volkow N., Wang G., Fowler J., Telang F. Overlapping neuronal circuits in addiction and obesity: Evidence of systems pathology. Philosophical Transactions of the Royal Society, B: Biological sciences 2008, 363(1507):3191-3200.
72. Vucetic Z., Reyes T. Central dopaminergic circuitry controlling food intake and reward: Implications for the regulation of obesity. Wiley Interdisciplinary Reviews: Systems Biology and Medicine 2010, 2(5):577-593.
73. Wargin W., Patrick K., Kilts C., Gualtieri T., Ellington K., Mueller R., et al. Pharmacokinetics of methyiphenidate in man, rat and monkey. The Journal of Pharmacology and Experimental Therapeutics 1983, 226(2):382-386.
74. Warren M., Werner H. The central stimulant action of some vasopressor amines. Journal of Pharmacology and Experimental Therapeutics 1945, 85:119.
75. Wickens J., Hyland B., Tripp G. Animal models to guide clinical drug development in ADHD: Lost in translation?. British Journal of Pharmacology 2011, 164(4):1107-1128.
76. Wooters T., Walton M., Bardo M. Oral methylphenidate establishes a conditioned place preference in rats. Neuroscience Letters 2011, 487:293-296.